3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- MYC_TARGETS_V2+0.620
- MYC_TARGETS_V1+0.610
- G2M_CHECKPOINT+0.510
- OXIDATIVE_PHOSPHORYLATION+0.400
- DNA_REPAIR+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.320
- MTORC1_SIGNALING+0.260
- MITOTIC_SPINDLE+0.180
- SPERMATOGENESIS+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- INFLAMMATORY_RESPONSE-0.480
- COAGULATION-0.460
- TGF_BETA_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.410
- UV_RESPONSE_DN-0.410
- ANGIOGENESIS-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.390
- IL2_STAT5_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.959 |
| 2 | SRR975602 | — | — | 0.946 |
| 3 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.940 |
| 4 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.935 |
| 5 | C3L-00993 | — | cohortSQ1 | 0.935 |
| 6 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.932 |
| 7 | ERR2208894 | — | — | 0.929 |
| 8 | SRR15030859 | — | — | 0.924 |
| 9 | 20090275.TNBC | — | E | 0.924 |
| 10 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |